By: Christopher A. Parrella, Esq., CPC, CHC, CPCO Parrella Health Law, Boston, Ma. A Health Law Defense and Compliance Firm

On August 2, 2024, a federal district court in Massachusetts refused to dismiss a qui tam action against Zimmer Biomet Holdings, Inc., a prominent manufacturer of orthopedic and medical devices. The case centers on allegations that Zimmer’s compensation structure for its independent contractor sales force violated the Anti-Kickback Statute (AKS), leading to the submission of false claims.

The lawsuit was initiated by Todd Langer, a former senior sales associate at Zimmer, who claimed that the company’s shift in 2015 from employing sales representatives to using independent contractors incentivized these contractors to prioritize profits over compliance. Langer argued that this commission-based compensation encouraged reps to steer healthcare providers toward using Zimmer products in government-funded procedures, thereby violating the AKS.

The court found that Langer sufficiently alleged that Zimmer’s practices crossed legal lines. Notably, Langer’s role as a whistleblower was bolstered by his position as an “original source” under the False Claims Act (FCA). Despite the fact that some details regarding Zimmer’s independent contractor model were publicly available prior to his lawsuit, Langer provided critical inside information that exposed the depth of the alleged kickback scheme. This included the intimate relationships between sales reps and surgeons, as well as specifics about the compensation and influence reps exerted over medical decisions.

Zimmer’s attempt to dismiss the case hinged on two main arguments: that its independent contractor arrangement was not inherently illegal and that the action should be barred under the FCA’s public disclosure rule. However, the court determined that the complaint’s details presented a plausible case under the AKS, especially given the similarities between this arrangement and a previous case involving Zimmer in 1999. The ruling underscores the importance of relators with insider knowledge in shining a light on nuanced schemes that might otherwise escape scrutiny.

The implications of this case are significant for the medical device industry, particularly for companies that rely heavily on independent contractor sales forces. As this action proceeds, it could set a precedent on how courts view commission-based compensation structures within the context of the AKS.

Conclusion and Call to Action

The ruling in United States ex rel. Langer v. Zimmer Biomet Holdings, Inc. serves as a powerful reminder that whistleblowers play a critical role in exposing fraud within the healthcare industry. If your organization employs independent contractors, especially in sales roles, it’s crucial to ensure that your compensation structures comply with federal law, including the Anti-Kickback Statute.

For further guidance on how this program could impact your business or to review your compliance policies, contact Parrella Health Law at 857-328-0382 or email Chris directly at cparrella@parrellahealthlaw.com. Our team is here to help you navigate these complex regulatory changes and protect your organization from legal exposure.